AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

AbbVie ($ABBV) has agreed to acquire the lead drug program from Gilgamesh Pharmaceuticals for up to $1.2 billion. The deal ...

AbbVie (ABBV) recently announced positive results from pivotal studies for its drug upadacitinib, which targeted severe ...

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and solutions to address complex health issues. It is set to report its Q3 2025 ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) dropped 0.2% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $204.55 and last traded at ...

At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

AbbVie (NYSE:ABBV – Get Free Report) had its price target hoisted by equities researchers at Guggenheim from $214.00 to $216.00 in a research report issued on Tuesday,Benzinga reports. The firm ...

AbbVie will acquire Gilgamesh's lead psychedelic drug for major depression in a deal worth up to $1.2 billion, following ...

AbbVie stock has had a good August, with double-digit MoM gains after seeing weakness for six months. Read the latest ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock ...